Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PROF
PROF logo

PROF Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Profound Medical Corp (PROF) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
6.610
1 Day change
2.96%
52 Week Range
8.950
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Profound Medical Corp (PROF) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The upcoming clinical CAPTAIN data presentation, strong revenue growth, and positive analyst sentiment provide a compelling case for investment. Despite the lack of recent trading signals and neutral insider/hedge fund activity, the stock's current price of $6.44 offers a reasonable entry point given its $12 price target and potential catalysts.

Technical Analysis

The MACD is positive at 0.125, indicating bullish momentum, though it is contracting. The RSI is neutral at 58.589, and moving averages are converging, suggesting no strong trend. Key support is at $5.853, and resistance levels are at $6.777 and $7.063, with the current price at $6.44 sitting near the pivot point of $6.315.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
0
Buy
10

Positive Catalysts

  • Upcoming clinical CAPTAIN data presentation at the European Association of Urology, which is considered a significant event for prostate cancer treatment.

  • Strong revenue growth of 43.13% YoY in Q4

  • Analyst maintains a Buy rating with a $12 price target, indicating significant upside potential.

Neutral/Negative Catalysts

  • Gross margin dropped by 5.86% YoY to 66.77%, indicating some pressure on profitability.

  • No recent news or significant insider/hedge fund activity to support immediate momentum.

Financial Performance

In Q4 2025, revenue increased by 43.13% YoY to $5,977,000, net income improved by 65.25% YoY to -$8,175,000, and EPS rose by 42.11% YoY to -$0.27. However, gross margin declined by 5.86% YoY to 66.77%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Lake Street analyst Ben Haynor maintains a Buy rating with a $12 price target, citing the upcoming CAPTAIN data presentation as a major overlooked catalyst. The analyst believes the current enterprise value of $140M is undervalued.

Wall Street analysts forecast PROF stock price to rise
3 Analyst Rating
Wall Street analysts forecast PROF stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.620
sliders
Low
11
Averages
11.67
High
12
Current: 6.620
sliders
Low
11
Averages
11.67
High
12
Lake Street
Ben Haynor
Buy
maintain
$12
AI Analysis
2026-03-09
Reason
Lake Street
Ben Haynor
Price Target
$12
AI Analysis
2026-03-09
maintain
Buy
Reason
Lake Street analyst Ben Haynor views last Friday's reaction to Profound Medical's Q4 results as "misguided" and resulting in "major news being overlooked," namely that the first clinical CAPTAIN data is being presented this Friday at the European Association of Urology. The analyst states that given this upcoming news, calling the study "one of the most important ever conducted in prostate cancer," does a roughly $140M enterprise value "sound reasonable for Profound? We think not." The firm keeps a Buy rating and $12 price target on Profound shares.
Lake Street
Buy
maintain
$11 -> $12
2026-01-07
Reason
Lake Street
Price Target
$11 -> $12
2026-01-07
maintain
Buy
Reason
Lake Street raised the firm's price target on Profound Medical to $12 from $11 and keeps a Buy rating on the shares. Profound raised gross proceeds of $36M via a registered direct offering and $6.45M in a private placement late last year and with "any capital concerns now behind the company," investors can focus on Profound's fundamental performance, the analyst argues.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PROF
Unlock Now

People Also Watch